Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Incidence, Current Guidelines and Management of Gastrointestinal Bleeding after Transcatheter Aortic Valve Replacement: A Systematic Review

Author(s): Devina Adalja, Harshvardhan Zala, Varun Victor, Aakash Sheth, Charles Willyard, Emi Suzuki, Harsh P. Patel, Monil Majmundar, Saraschandra Vallabhajosyula and Rajkumar Doshi*

Volume 19, Issue 1, 2023

Published on: 27 August, 2022

Article ID: e230622206351 Pages: 13

DOI: 10.2174/1573403X18666220623150830

Price: $65

Abstract

Background: There is a significant increase in morbidity and mortality in patients complicated by major bleeding following transcatheter aortic valve replacement (TAVR). It has become more challenging to manage such complications when the patient needs to be on anticoagulation or antiplatelet agent post-procedure to prevent thrombotic/embolic complications.

Methods: We systematically reviewed all available randomized controlled trials and observational studies to identify incidence rates of gastrointestinal bleeding post-procedure. After performing a systematic search, a total of 8731 patients from 15 studies (5 RCTs and 10 non-RCTs) were included in this review.

Results: The average rate of gastrointestinal bleeding during follow-up was 3.0% in randomized controlled trials and 1.9% among observational studies.

Conclusion: Gastrointestinal bleeding has been noted to be higher in the RCTs as compared to observational studies. This review expands knowledge of current guidelines and possible management of patients undergoing TAVR.

Keywords: Transcatheter aortic valve implantation, gastrointestinal bleeding, anticoagulation, antiplatelet, review, TAVR.

[1]
Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187-98.
[http://dx.doi.org/10.1056/NEJMoa1103510] [PMID: 21639811]
[2]
Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366(18): 1686-95.
[http://dx.doi.org/10.1056/NEJMoa1200384] [PMID: 22443479]
[3]
Généreux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol 2014; 64(24): 2605-15.
[http://dx.doi.org/10.1016/j.jacc.2014.08.052] [PMID: 25524339]
[4]
Rodés-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62(25): 2349-59.
[http://dx.doi.org/10.1016/j.jacc.2013.03.029] [PMID: 23583252]
[5]
Piccolo R, Pilgrim T, Franzone A, et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017; 10(14): 1436-46.
[http://dx.doi.org/10.1016/j.jcin.2017.04.034] [PMID: 28728657]
[6]
Naoum C, Blanke P, Dvir D, et al. Clinical outcomes and imaging findings in women undergoing TAVR. JACC Cardiovasc Imaging 2016; 9(4): 483-93.
[http://dx.doi.org/10.1016/j.jcmg.2016.02.009] [PMID: 27056166]
[7]
Doshi R, Shlofmitz E, Meraj P. Comparison of outcomes and complications of transcatheter aortic valve implantation in women versus men (from the National Inpatient Sample). Am J Cardiol 2018; 121(1): 73-7.
[http://dx.doi.org/10.1016/j.amjcard.2017.09.015] [PMID: 29103601]
[8]
Stanger DE, Abdulla AH, Wong FT, et al. Upper gastrointestinal bleeding following transcatheter aortic valve replacement: A retrospective analysis. Catheter Cardiovasc Interv 2017; 90(2): E53-61.
[http://dx.doi.org/10.1002/ccd.26650] [PMID: 27392808]
[9]
Konigstein M, Havakuk O, Arbel Y, et al. Impact of hemoglobin drop, bleeding events, and red blood cell transfusions on long-term mortality in patients undergoing transaortic valve implantation. Can J Cardiol 2016; 32(10): 1239.e9-1239.e14.
[http://dx.doi.org/10.1016/j.cjca.2015.10.032] [PMID: 26927856]
[10]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151(4): 264-9.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[11]
Ichibori Y, Mizote I, Maeda K, et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone. Circ J 2017; 81(3): 397-404.
[http://dx.doi.org/10.1253/circj.CJ-16-0903] [PMID: 28123149]
[12]
Kleczynski P, Dziewierz A, Bagienski M, et al. Association between blood transfusions and 12-month mortality after transcatheter aortic valve implantation. Int Heart J 2017; 58(1): 50-5.
[http://dx.doi.org/10.1536/ihj.16-131] [PMID: 28077819]
[13]
Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: The arte (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv 2017; 10(13): 1357-65.
[http://dx.doi.org/10.1016/j.jcin.2017.04.014] [PMID: 28527771]
[14]
Kibler M, Marchandot B, Messas N, et al. Primary hemostatic disorders and late major bleeding after transcatheter aortic valve replacement. J Am Coll Cardiol 2018; 72(18): 2139-48.
[http://dx.doi.org/10.1016/j.jacc.2018.08.2143] [PMID: 30360823]
[15]
Tarantini G, Gasparetto V, Napodano M, et al. Transcatheter aortic valve implantation and bleeding: Focus on valve academic research consortium-2 classification. Int J Cardiol 2013; 168(5): 5001-3.
[http://dx.doi.org/10.1016/j.ijcard.2013.07.123] [PMID: 23931971]
[16]
Leclercq F, Akodad M, Macia JC, et al. Vascular complications and bleeding after transfemoral transcatheter aortic valve implantation performed through open surgical access. Am J Cardiol 2015; 116(9): 1399-404.
[http://dx.doi.org/10.1016/j.amjcard.2015.08.003] [PMID: 26414600]
[17]
Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2016; 9(16): 1706-17.
[http://dx.doi.org/10.1016/j.jcin.2016.06.025] [PMID: 27539691]
[18]
Hioki H, Watanabe Y, Kozuma K, et al. Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding. Heart 2017; 103(5): 361-7.
[http://dx.doi.org/10.1136/heartjnl-2016-309735] [PMID: 27540180]
[19]
Czerwińska-Jelonkiewicz K, Zembala M, Dąbrowski M, et al. Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry - POL-TAVI. Int J Cardiol 2017; 227: 305-11.
[http://dx.doi.org/10.1016/j.ijcard.2016.11.095] [PMID: 27843052]
[20]
Geis NA, Kiriakou C, Chorianopoulos E, Pleger ST, Katus HA, Bekeredjian R. Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention 2017; 12(17): 2058-66.
[http://dx.doi.org/10.4244/EIJ-D-15-00259] [PMID: 28433958]
[21]
Geis NA, Kiriakou C, Chorianopoulos E, Uhlmann L, Katus HA, Bekeredjian R. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol 2018; 107(9): 799-806.
[http://dx.doi.org/10.1007/s00392-018-1247-x] [PMID: 29644411]
[22]
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Investigators E-TA. edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 2021; 385(23): 2150-60.
[http://dx.doi.org/10.1056/NEJMoa2111016]
[23]
Ando T, Takagi H, Briasoulis A, Afonso L. Single versus dual anti-platelet therapy post transcatheter aortic valve implantation: A meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2017; 44(4): 448-56.
[http://dx.doi.org/10.1007/s11239-017-1550-9] [PMID: 28905178]
[24]
Kuno T, Takagi H, Sugiyama T, et al. Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network meta-analysis. Catheter Cardiovasc Interv 2020; 96(2): E177-86.
[http://dx.doi.org/10.1002/ccd.28498] [PMID: 31609071]
[25]
Ma X, Xu Z, Li J, et al. Antiplatelet strategy after transcatheter aortic valve replacement: An updated meta-analysis. J Cardiovasc Surg 2019; 60(5): 624-32.
[http://dx.doi.org/10.23736/S0021-9509.19.10833-6] [PMID: 31486613]
[26]
Gandhi S, Schwalm JD, Velianou JL, Natarajan MK, Farkouh ME. Comparison of dual-antiplatelet therapy to mono-antiplatelet therapy after transcatheter aortic valve implantation: Systematic review and meta-analysis. Can J Cardiol 2015; 31(6): 775-84.
[http://dx.doi.org/10.1016/j.cjca.2015.01.014] [PMID: 25913473]
[27]
Raheja H, Garg A, Goel S, et al. Comparison of single versus dual antiplatelet therapy after TAVR: A systematic review and meta-analysis. Catheter Cardiovasc Interv 2018; 92(4): 783-91.
[http://dx.doi.org/10.1002/ccd.27582] [PMID: 29516608]
[28]
Alrifai A, Soud M, Kabach A, et al. Dual antiplatelet therapy versus single antiplatelet therapy after transaortic valve replacement: Meta-analysis. Cardiovasc Revasc Med 2018; 19(6S): 47-52.
[http://dx.doi.org/10.1016/j.carrev.2018.03.008] [PMID: 29580827]
[29]
Turgeon RD, Barry AR. Single vs dual antiplatelet therapy following transcatheter aortic valve implantation: A systematic review. Clin Cardiol 2015; 38(10): 629-34.
[http://dx.doi.org/10.1002/clc.22426] [PMID: 26239886]
[30]
Hu X, Yang FY, Wang Y, Zhang Y, Chen M. Single versus dual antiplatelet therapy after transcatheter aortic valve implantation: A systematic review and meta-analysis. Cardiology 2018; 141(1): 52-65.
[http://dx.doi.org/10.1159/000490307] [PMID: 30368490]
[31]
Osman M, Syed M, Balla S, Kheiri B, Golwala H, Zahr F. Meta-analysis of aspirin monotherapy versus dual antiplatelet therapy after transcatheter aortic valve implantation. Am J Cardiol 2020; 135: 187-8.
[http://dx.doi.org/10.1016/j.amjcard.2020.09.024] [PMID: 32961110]
[32]
Maes F, Stabile E, Ussia GP, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol 2018; 122(2): 310-5.
[http://dx.doi.org/10.1016/j.amjcard.2018.04.006] [PMID: 29861051]
[33]
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The valve academic research consortium-2 consensus document. J Am Coll Cardiol 2012; 60(15): 1438-54.
[http://dx.doi.org/10.1016/j.jacc.2012.09.001] [PMID: 23036636]
[34]
Sherwood MW, Xiang K, Matsouaka R, et al. Incidence, temporal trends, and associated outcomes of vascular and bleeding complications in patients undergoing transfemoral transcatheter aortic valve replacement: Insights from the society of thoracic surgeons/American college of cardiology transcatheter valve therapies registry. Circ Cardiovasc Interv 2020; 13(1): e008227.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.119.008227] [PMID: 31937138]
[35]
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143(5): e35-71.
[http://dx.doi.org/10.1161/CIR.0000000000000932] [PMID: 33332149]
[36]
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38(36): 2739-91.
[http://dx.doi.org/10.1093/eurheartj/ehx391] [PMID: 28886619]
[37]
Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: pp. (2 Suppl)e576S-600S.
[38]
Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369(13): 1206-14.
[http://dx.doi.org/10.1056/NEJMoa1300615] [PMID: 23991661]
[39]
Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020; 383(15): 1447-57.
[http://dx.doi.org/10.1056/NEJMoa2017815] [PMID: 32865376]
[40]
Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: A consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021; 42(23): 2265-9.
[http://dx.doi.org/10.1093/eurheartj/ehab196] [PMID: 33822924]
[41]
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382(2): 120-9.
[http://dx.doi.org/10.1056/NEJMoa1911425] [PMID: 31733180]
[42]
de Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med 2020; 382(2): 130-9.
[http://dx.doi.org/10.1056/NEJMoa1911426] [PMID: 31733182]
[43]
Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020; 382(18): 1696-707.
[http://dx.doi.org/10.1056/NEJMoa1915152] [PMID: 32223116]
[44]
Kosmidou I, Liu Y, Alu MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv 2019; 12(16): 1580-9.
[http://dx.doi.org/10.1016/j.jcin.2019.06.001] [PMID: 31439338]
[45]
Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108(12): 1772-6.
[http://dx.doi.org/10.1016/j.amjcard.2011.07.049] [PMID: 21907949]
[46]
Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174(3): 624-7.
[http://dx.doi.org/10.1016/j.ijcard.2014.04.170] [PMID: 24809922]
[47]
Balan P, Zhao Y, Johnson S, et al. The society of thoracic surgery risk score as a predictor of 30-day mortality in transcatheter vs surgical aortic valve replacement: A single-center experience and its implications for the development of a TAVR risk-prediction model. J Invasive Cardiol 2017; 29(3): 109-14.
[PMID: 28255105]
[48]
Wang J, Yu W, Jin Q, et al. Risk factors for post-TAVI bleeding according to the VARC-2 bleeding definition and effect of the bleeding on short-term mortality: A meta-analysis. Can J Cardiol 2017; 33(4): 525-34.
[http://dx.doi.org/10.1016/j.cjca.2016.12.001] [PMID: 28256429]
[49]
Godino C, Lauretta L, Pavon AG, et al. Heyde’s syndrome incidence and outcome in patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol 2013; 61(6): 687-9.
[http://dx.doi.org/10.1016/j.jacc.2012.10.041] [PMID: 23391203]
[50]
Desai R, Parekh T, Singh S, et al. Alarming increasing trends in hospitalizations and mortality with heyde’s syndrome: A nationwide inpatient perspective (2007 to 2014). Am J Cardiol 2019; 123(7): 1149-55.
[http://dx.doi.org/10.1016/j.amjcard.2018.12.043] [PMID: 30660352]
[51]
Nijenhuis VJ, Bennaghmouch N, van Kuijk JP, Capodanno D, ten Berg JM. Antithrombotic treatment in patients undergoing Transcatheter Aortic Valve Implantation (TAVI). Thromb Haemost 2015; 113(4): 674-85.
[http://dx.doi.org/10.1160/TH14-10-0821] [PMID: 25653053]
[52]
Lynch DR Jr, Dantzler D, Robbins M, Zhao D. Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis 2013; 35(4): 476-82.
[http://dx.doi.org/10.1007/s11239-013-0886-z] [PMID: 23420510]
[53]
Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170(16): 1433-41.
[http://dx.doi.org/10.1001/archinternmed.2010.271] [PMID: 20837828]
[54]
Kallmeyer IJ, Collard CD, Fox JA, Body SC, Shernan SK. The safety of intraoperative transesophageal echocardiography: A case series of 7200 cardiac surgical patients. Anesth Analg 2001; 92(5): 1126-30.
[http://dx.doi.org/10.1097/00000539-200105000-00009] [PMID: 11323333]
[55]
Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: A meta-analysis. J Gastroenterol Hepatol 2005; 20(1): 11-25.
[http://dx.doi.org/10.1111/j.1440-1746.2004.03441.x] [PMID: 15610441]
[56]
Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: A population-based study. Gastroenterology 2015; 149(3): 586-95.e3.
[http://dx.doi.org/10.1053/j.gastro.2015.05.002] [PMID: 25960019]
[57]
Mo C, Sun G, Wang YZ, Lu ML, Yang YS. PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: Systematic review and meta-analysis. PLoS One 2015; 10(7): e0131558.
[http://dx.doi.org/10.1371/journal.pone.0131558] [PMID: 26147767]
[58]
Vaduganathan M, Bhatt DL, Cryer BL, et al. Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy. J Am Coll Cardiol 2016; 67(14): 1661-71.
[http://dx.doi.org/10.1016/j.jacc.2015.12.068] [PMID: 27012778]
[59]
Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4(11): 2508-9.
[http://dx.doi.org/10.1111/j.1538-7836.2006.02162.x] [PMID: 16898956]
[60]
Grove EL, Würtz M, Schwarz P, Jørgensen NR, Vestergaard P. Gastrointestinal events with clopidogrel: A nationwide population-based cohort study. J Gen Intern Med 2013; 28(2): 216-22.
[http://dx.doi.org/10.1007/s11606-012-2208-0] [PMID: 22948933]
[61]
Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170(8): 704-10.
[http://dx.doi.org/10.1001/archinternmed.2010.34] [PMID: 20421557]
[62]
Yi X, Zhou Q, Wang C, Lin J, Cheng W, Chi L. Concomitant use of proton pump inhibitors and clopidogrel is not associated with adverse outcomes after ischemic stroke in Chinese population. J Stroke Cerebrovasc Dis 2016; 25(12): 2859-67.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.08.001] [PMID: 27546731]
[63]
Lavie CJ, Howden CW, Scheiman J, Tursi J. Upper gastrointestinal toxicity associated with long-term aspirin therapy: Consequences and prevention. Curr Probl Cardiol 2017; 42(5): 146-64.
[http://dx.doi.org/10.1016/j.cpcardiol.2017.01.006] [PMID: 28363584]
[64]
Abraham NS, Graham DY. NSAIDs and gastrointestinal complications: New clinical challenges. Expert Opin Pharmacother 2005; 6(15): 2681-9.
[http://dx.doi.org/10.1517/14656566.6.15.2681] [PMID: 16316306]
[65]
Chan WH, Khin LW, Chung YF, Goh YC, Ong HS, Wong WK. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg 2011; 98(5): 640-4.
[http://dx.doi.org/10.1002/bjs.7420] [PMID: 21305536]
[66]
Gisbert JP, González L, Calvet X, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2-antagonists: A meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15(7): 917-26.
[http://dx.doi.org/10.1046/j.1365-2036.2001.01012.x] [PMID: 11421865]
[67]
Valgimigli M, Bueno H, Byrne RA, et al. Guidelines ESCC for P, Societies ESCNC. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Heart J 2018; 39(3): 213-60.
[http://dx.doi.org/10.1093/eurheartj/ehx419] [PMID: 28886622]
[68]
Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Ann Intern Med 2010; 152(1): 1-9.
[http://dx.doi.org/10.7326/0003-4819-152-1-201001050-00179] [PMID: 19949136]
[69]
Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper gastrointestinal haemorrhage. Aliment Pharmacol Ther 2012; 36(1): 30-6.
[http://dx.doi.org/10.1111/j.1365-2036.2012.05129.x] [PMID: 22577955]
[70]
Garg SK, Anugwom C, Campbell J, et al. Early esophagogastroduodenoscopy is associated with better Outcomes in upper gastrointestinal bleeding: A nationwide study. Endosc Int Open 2017; 5(5): E376-86.
[http://dx.doi.org/10.1055/s-0042-121665] [PMID: 28512647]
[71]
Sung JJ, Chan FK, Lau JY, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: A randomized comparison. Ann Intern Med 2003; 139(4): 237-43.
[http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00005] [PMID: 12965978]
[72]
Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008; 57(9): 1322-9.
[http://dx.doi.org/10.1136/gut.2007.142497] [PMID: 18469092]
[73]
Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107(3): 345-60.
[http://dx.doi.org/10.1038/ajg.2011.480] [PMID: 22310222]
[74]
Hamm CW, Bassand JP, Agewall S, et al. Guidelines ESCC for P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 2011; 32(23): 2999-3054.
[http://dx.doi.org/10.1093/eurheartj/ehr236] [PMID: 21873419]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy